171 related articles for article (PubMed ID: 19156622)
1. Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications.
Lindsey JB; Cipollone F; Abdullah SM; McGuire DK
Diab Vasc Dis Res; 2009 Jan; 6(1):7-14. PubMed ID: 19156622
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
Microvasc Res; 2008 May; 76(1):52-6. PubMed ID: 18474381
[TBL] [Abstract][Full Text] [Related]
3. Association of polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating RAGE levels.
Gaens KH; Ferreira I; van der Kallen CJ; van Greevenbroek MM; Blaak EE; Feskens EJ; Dekker JM; Nijpels G; Heine RJ; 't Hart LM; de Groot PG; Stehouwer CD; Schalkwijk CG
J Clin Endocrinol Metab; 2009 Dec; 94(12):5174-80. PubMed ID: 19890027
[TBL] [Abstract][Full Text] [Related]
4. The AGE/RAGE axis in diabetes-accelerated atherosclerosis.
Jandeleit-Dahm K; Watson A; Soro-Paavonen A
Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):329-34. PubMed ID: 18290873
[TBL] [Abstract][Full Text] [Related]
5. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects.
Yamagishi S; Adachi H; Nakamura K; Matsui T; Jinnouchi Y; Takenaka K; Takeuchi M; Enomoto M; Furuki K; Hino A; Shigeto Y; Imaizumi T
Metabolism; 2006 Sep; 55(9):1227-31. PubMed ID: 16919543
[TBL] [Abstract][Full Text] [Related]
6. Receptor for Advanced Glycation Endproducts (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging.
Yan SF; D'Agati V; Schmidt AM; Ramasamy R
Curr Mol Med; 2007 Dec; 7(8):699-710. PubMed ID: 18331228
[TBL] [Abstract][Full Text] [Related]
7. Effect of insulin on the soluble receptor for advanced glycation end products (RAGE).
Lam JK; Wang Y; Shiu SW; Wong Y; Betteridge DJ; Tan KC
Diabet Med; 2013 Jun; 30(6):702-9. PubMed ID: 23432638
[TBL] [Abstract][Full Text] [Related]
8. Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans.
Jang Y; Kim JY; Kang SM; Kim JS; Chae JS; Kim OY; Koh SJ; Lee HC; Ahn CW; Song YD; Lee JH
Metabolism; 2007 Feb; 56(2):199-205. PubMed ID: 17224333
[TBL] [Abstract][Full Text] [Related]
9. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
Yamagishi S; Matsui T; Nakamura K
Curr Drug Targets; 2007 Oct; 8(10):1138-43. PubMed ID: 17979674
[TBL] [Abstract][Full Text] [Related]
10. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes.
Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
Diabetes Metab Res Rev; 2008 Feb; 24(2):109-14. PubMed ID: 17694504
[TBL] [Abstract][Full Text] [Related]
11. Advanced glycation and endothelial functions: a link towards vascular complications in diabetes.
Rojas A; Morales MA
Life Sci; 2004 Dec; 76(7):715-30. PubMed ID: 15581904
[TBL] [Abstract][Full Text] [Related]
12. Intrafollicular soluble receptor for advanced glycation end products (sRAGE) and embryo quality in assisted reproduction.
Bonetti TC; Borges E; Braga DP; Iaconelli A; Kleine JP; Silva ID
Reprod Biomed Online; 2013 Jan; 26(1):62-7. PubMed ID: 23182743
[TBL] [Abstract][Full Text] [Related]
13. Elevated serum levels of advanced glycation end products and their monocyte receptors in patients with type 2 diabetes.
Su XD; Li SS; Tian YQ; Zhang ZY; Zhang GZ; Wang LX
Arch Med Res; 2011 Oct; 42(7):596-601. PubMed ID: 22100610
[TBL] [Abstract][Full Text] [Related]
14. Receptor for advanced glycation end products (RAGE)--soluble form (sRAGE) and gene polymorphisms in patients with breast cancer.
Tesarová P; Kalousová M; Jáchymová M; Mestek O; Petruzelka L; Zima T
Cancer Invest; 2007 Dec; 25(8):720-5. PubMed ID: 18058469
[TBL] [Abstract][Full Text] [Related]
15. Soluble receptor for advanced glycation end-products (sRAGE) and polymorphisms of RAGE and glyoxalase I genes in patients with pancreas cancer.
Krechler T; Jáchymová M; Mestek O; Zák A; Zima T; Kalousová M
Clin Biochem; 2010 Jul; 43(10-11):882-6. PubMed ID: 20398646
[TBL] [Abstract][Full Text] [Related]
16. The RAGE axis and endothelial dysfunction: maladaptive roles in the diabetic vasculature and beyond.
Ramasamy R; Yan SF; Schmidt AM
Trends Cardiovasc Med; 2005 Oct; 15(7):237-43. PubMed ID: 16226677
[TBL] [Abstract][Full Text] [Related]
17. An update on advanced glycation endproducts and atherosclerosis.
Del Turco S; Basta G
Biofactors; 2012; 38(4):266-74. PubMed ID: 22488968
[TBL] [Abstract][Full Text] [Related]
18. Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients.
Yamagishi S; Nakamura K; Inoue H
Med Hypotheses; 2005; 65(6):1013-5. PubMed ID: 16146671
[TBL] [Abstract][Full Text] [Related]
19. Enhanced interaction of advanced glycation end products with their cellular receptor RAGE: implications for the pathogenesis of accelerated periodontal disease in diabetes.
Lalla E; Lamster IB; Schmidt AM
Ann Periodontol; 1998 Jul; 3(1):13-9. PubMed ID: 9722686
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products.
Kaji Y; Usui T; Ishida S; Yamashiro K; Moore TC; Moore J; Yamamoto Y; Yamamoto H; Adamis AP
Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):858-65. PubMed ID: 17251488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
